Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Psychosocial Support May Improve Cancer-Related Fatigue

      June 13, 2019
      By Brielle Benyon
      Article
      Conferences|ONS Annual Congress

      Cognitive behavioral therapy help to improve the lives of patients experiencing cancer-related fatigue.

      Fatigue is one of the most common symptoms reported by gynecologic cancer survivors, with about half (49%) of women presenting with clinically significant fatigue at diagnosis, and 42% experiencing persisting fatigue a year later.

      When it comes to addressing cancer-related fatigue, oncology nurses might want to ask their patients about their social support system, as well as present the idea of cognitive behavioral therapy (CBT), which may be able to help, according to research conducted at the Dana-Farber Cancer Institute and the Netherlands Comprehensive Cancer Organisation.

      “My experience in managing patients who experience cancer-related fatigue is that it’s often one of the most burdensome symptoms, and it impacts many aspects of their lives,” said Hanneke Poort, PhD, a psychologist and post-doctoral research fellow in the Department of Psychosocial Psychology and Palliative Care at the Dana-Farber Cancer Institute.

      “Patients often don’t know that this is something that can be addressed, so they either do not report it to their doctors, or they feel that it is just something they have to live with. But fortunately, there are interventions that we can use to reduce [fatigue].”

      While previous research has shown that exercise can benefit patients experiencing fatigue, Poort focused on CBT, which focuses on cancer-related factors — like fatigue – that persist over time.

      Poort noted that patients with cancer can often catastrophize their fatigue and see it as an awful symptom that may never get better. Or, especially for those with advanced disease, individuals are burdened with a feeling of uncertainty about their illness and treatment. These two factors can exacerbate fatigue, but CBT may be able to help.

      Additionally, social support systems may play a role in fatigue as well, Poort explained.

      “Fatigue is a very invisible symptom, and it can be hard for patients — especially if they receive cancer treatments for a long time – to receive the support that they want,” Poort said. “We would talk to them about the potential discrepancy between the actual and perceived social support, and also teach them how they can communicate more assertively about the things that they might need in terms of support.”

      Addressing the psychological side of fatigue is key in combatting the malady. In their study — which looked at 312 women with ovarian or endometrial cancer – the most important factor contributing to fatigue at baseline was depressive symptoms.

      “Fortunately, there are interventions focusing on the psychological factors that have been shown to be helpful in reducing fatigue,” Poort said. “So, at Dana-Farber, we are currently adapting the CBT intervention that we previously tested in a larger sample of patients for women taking PARP inhibitors for advanced ovarian cancer. I think this is a really exciting study because it would be great if we can improve the quality of life for women taking these new, promising treatments.”

      As new cancer treatments like PARP inhibitors continue to become available for women with gynecologic cancer, it is crucial to gain a better understanding of how patients tolerate the drugs, and any adverse events — like severe or chronic fatigue – that they might have.

      These advancements, Poort said, may be laying the groundwork for future research.

      “I also think that one of the new areas that would be really interesting for research is to look more into tolerance of uncertainty while being on these prolonged therapies,” she said. “There’s going to be many changes in the course of treatment where they might not respond to treatment anymore, and they might have to adjust. We don’t know a lot about how patients deal with these changes for a longer period of time.”

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a man wearing a suit in front of an Oncology Nursing News backdrop
      Photo of a man wearing a suit in front of an Oncology Nursing News backdrop
      Related Content

      Illustration of a lung under a magnifying glass

      Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC

      Kristi Rosa
      September 16th 2025
      Article

      The Vitals

      Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

      Lindsay Fischer
      September 16th 2025
      Podcast

      Illustration of clinicians investigating a large illustrated lung

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Jax DiEugenio
      September 16th 2025
      Article

      The Vitals

      Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

      Lindsay Fischer
      September 16th 2025
      Podcast

      Image of blood cancer cells

      Subcutaneous Daratumumab Reduces Smoldering Myeloma Progression

      Russ Conroy
      September 16th 2025
      Article

      Image of bone marrow with cancer cells

      GLP-1a Associated With Better Outcomes for Those With Polycythemia Vera

      Ryan Scott
      September 16th 2025
      Article
      Related Content

      Illustration of a lung under a magnifying glass

      Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC

      Kristi Rosa
      September 16th 2025
      Article

      The Vitals

      Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

      Lindsay Fischer
      September 16th 2025
      Podcast

      Illustration of clinicians investigating a large illustrated lung

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Jax DiEugenio
      September 16th 2025
      Article

      The Vitals

      Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

      Lindsay Fischer
      September 16th 2025
      Podcast

      Image of blood cancer cells

      Subcutaneous Daratumumab Reduces Smoldering Myeloma Progression

      Russ Conroy
      September 16th 2025
      Article

      Image of bone marrow with cancer cells

      GLP-1a Associated With Better Outcomes for Those With Polycythemia Vera

      Ryan Scott
      September 16th 2025
      Article

      Latest Conference Coverage

      Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care

      Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC

      Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs

      Safety Management With Amivantamab Plus Lazertinib in NSCLC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      259 Prospect Plains Rd, Bldg H,
      Monroe, NJ 08831

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.